Targeting MTHFD2 in acute myeloid leukemia

Area of Science:

• Oncology
• Metabolic pathways
• Cancer biology

Background:

• Metabolic pathway dysregulation is crucial in cancer development.
• The one-carbon folate pathway, particularly methylenetetrahydrofolate dehydrogenase-cyclohydrolase 2 (MTHFD2), is implicated in cancer metabolism.
• MTHFD2 is significantly overexpressed in cancer cells compared to normal cells.

Purpose of the Study:

• To investigate MTHFD2 as a potential therapeutic target in acute myeloid leukemia (AML).
• To evaluate the impact of MTHFD2 inhibition on AML progression and patient outcomes.
• To identify biomarkers predictive of response to MTHFD2-targeted therapies.

Main Methods:

• Functional genomic screening and knockdown experiments in AML cell lines and patient samples.
• In vivo studies using human xenograft and MLL-AF9 mouse leukemia models.
• Analysis of primary patient AML data to correlate MTHFD2 expression with treatment response.
• Investigating the mechanistic link between MYC, MTHFD2, and the TCA cycle.

Main Results:

• MTHFD2 knockdown in AML cells led to reduced proliferation, induced differentiation, and impaired colony formation.
• Suppression of MTHFD2 in vivo decreased leukemia burden and extended survival in mouse models.
• FLT3-ITD was identified as a predictive biomarker for response to MTHFD2 suppression.
• MYC was found to regulate MTHFD2 expression, and MTHFD2 inhibition disrupted the TCA cycle.

Conclusions:

• MTHFD2 is a critical metabolic enzyme in AML pathogenesis.
• Targeting MTHFD2 demonstrates significant therapeutic potential in AML models.
• FLT3-ITD status can guide patient selection for MTHFD2-targeted therapies.